This article was originally published in Pharmaceutical Approvals Monthly
Oral form of the antipsychotic agent, formerly known as Zeldox, is approved Feb. 5. A March launch is planned. Although the drug is not restricted to second-line use, labeling recommends physicians first consider prescribing other agents that have lower rates of QT prolongation. "Whether ziprasidone will cause torsades de pointes or increase the rate of sudden death is not yet known," labeling states. A boxed warning, recommended by FDA's Psychopharmacologic Drugs Advisory Committee, is not in labeling. Among the potential tradenames under discussion is Geodon. An intramuscular formulation of ziprasidone is scheduled for review by the psychopharm committee Feb. 1
You may also be interested in...
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.